How do you advise scheduling follow-up visits for patients on tirbanibulin, knowing pivotal trial endpoints extended to 57 days?

Featuring Vishal Patel, MD, FAAD, FACMS | Associate Professor of Dermatology, GW School of Medicine &Health SciencesDirector of Cutaneous Oncology, GW Cancer CenterDirector of Dermatological Surgery, GW Department of Dermatology | Published October 17, 2025